MedPath

Renal Outcomes in the early use of vasopressin in the treatment of septic shock

Phase 1
Recruiting
Conditions
Septic shock
MedDRA version: 20.0Level: PTClassification code: 10040070Term: Septic shock Class: 100000004862
Therapeutic area: Diseases [C] - Virus Diseases [C02]
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]
Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Registration Number
CTIS2023-509071-16-00
Lead Sponsor
Azienda Unita Sanitaria Locale Di Bologna
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
242
Inclusion Criteria

Patients suffering from septic shock hospitalized in an intensive setting within 24 hours of clinical diagnosis, Capable of expressing informed consent to treatment, Aged over 18 years and under 80 years of age, Male and female, Norepinephrine dosage equal to or greater than 0.25 mcg/kg/min according to the patient's ideal weight (IBW)

Exclusion Criteria

Patients in the absence of consent to participate in the study and to the processing of personal and particular data, Single kidney patients, Patients with bilateral renal hypoplasia, Patients undergoing kidney transplant, Patients undergoing haemoperfusion with an adsorbent cartridge for bacterial endotoxin, Patients under 18 years of age or over 80 years of age, Patients who died within the first 24 hours of admission to the ICU, Patients requiring a norepinephrine dosage lower than 0.25 mcg/kg/min in the first 24 hours of hospitalization in the ICU, Patients with recent acute coronary syndrome (within the previous 7 days), Patients with allergy/intolerance to the drugs used in the study, Pregnant patients, Patients who need to start renal replacement treatment within 24 hours of admission to the ICU for dialysis emergencies that cannot be deferred, Patients with a history of end-stage renal failure or already undergoing dialysis treatment (CKD stages 4 and 5, with glomerular filtration < 30 ml/min)

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath